| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Study design and cohort characteristics of the Childhood Cancer Survivor Study: a multi-institutional collaborative project.
|
Med Pediatr Oncol
|
2002
|
8.03
|
|
2
|
The Childhood Cancer Survivor Study: a National Cancer Institute-supported resource for outcome and intervention research.
|
J Clin Oncol
|
2009
|
5.86
|
|
3
|
New primary neoplasms of the central nervous system in survivors of childhood cancer: a report from the Childhood Cancer Survivor Study.
|
J Natl Cancer Inst
|
2006
|
3.90
|
|
4
|
Long-term outcomes among adult survivors of childhood central nervous system malignancies in the Childhood Cancer Survivor Study.
|
J Natl Cancer Inst
|
2009
|
3.52
|
|
5
|
Postoperative cerebellar mutism syndrome following treatment of medulloblastoma: neuroradiographic features and origin.
|
J Neurosurg Pediatr
|
2010
|
2.92
|
|
6
|
Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis.
|
Lancet Oncol
|
2013
|
2.82
|
|
7
|
Stroke as a late treatment effect of Hodgkin's Disease: a report from the Childhood Cancer Survivor Study.
|
J Clin Oncol
|
2005
|
2.76
|
|
8
|
Late-occurring stroke among long-term survivors of childhood leukemia and brain tumors: a report from the Childhood Cancer Survivor Study.
|
J Clin Oncol
|
2006
|
2.71
|
|
9
|
Incidence and severity of postoperative cerebellar mutism syndrome in children with medulloblastoma: a prospective study by the Children's Oncology Group.
|
J Neurosurg
|
2006
|
2.31
|
|
10
|
Neurocognitive status in long-term survivors of childhood CNS malignancies: a report from the Childhood Cancer Survivor Study.
|
Neuropsychology
|
2009
|
2.29
|
|
11
|
Chronic disease in the Childhood Cancer Survivor Study cohort: a review of published findings.
|
J Clin Oncol
|
2009
|
2.23
|
|
12
|
Psychological outcomes in long-term survivors of childhood brain cancer: a report from the childhood cancer survivor study.
|
J Clin Oncol
|
2004
|
2.15
|
|
13
|
Endocrine and cardiovascular late effects among adult survivors of childhood brain tumors: Childhood Cancer Survivor Study.
|
Cancer
|
2003
|
2.11
|
|
14
|
Medulloblastoma in childhood: new biological advances.
|
Lancet Neurol
|
2007
|
1.93
|
|
15
|
Randomized study of two chemotherapy regimens for treatment of low-grade glioma in young children: a report from the Children's Oncology Group.
|
J Clin Oncol
|
2012
|
1.88
|
|
16
|
Cytogenetic prognostication within medulloblastoma subgroups.
|
J Clin Oncol
|
2014
|
1.56
|
|
17
|
Long-term outcomes of adult survivors of childhood cancer.
|
Cancer
|
2005
|
1.53
|
|
18
|
A molecular biology and phase II trial of lapatinib in children with refractory CNS malignancies: a pediatric brain tumor consortium study.
|
J Neurooncol
|
2013
|
1.51
|
|
19
|
The role of INI1 and the SWI/SNF complex in the development of rhabdoid tumors: meeting summary from the workshop on childhood atypical teratoid/rhabdoid tumors.
|
Cancer Res
|
2002
|
1.51
|
|
20
|
Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumor Consortium study.
|
J Clin Oncol
|
2010
|
1.50
|
|
21
|
Cerebrovascular abnormalities in a population of children with neurofibromatosis type 1.
|
Neurology
|
2005
|
1.50
|
|
22
|
A prognostic gene expression signature in infratentorial ependymoma.
|
Acta Neuropathol
|
2012
|
1.44
|
|
23
|
Final height and body mass index among adult survivors of childhood brain cancer: childhood cancer survivor study.
|
J Clin Endocrinol Metab
|
2003
|
1.39
|
|
24
|
Phase I trial of MK-0752 in children with refractory CNS malignancies: a pediatric brain tumor consortium study.
|
J Clin Oncol
|
2011
|
1.39
|
|
25
|
Proceedings from the 2009 genetic syndromes of the Ras/MAPK pathway: From bedside to bench and back.
|
Am J Med Genet A
|
2010
|
1.36
|
|
26
|
Phase I trial of single-dose temozolomide and continuous administration of o6-benzylguanine in children with brain tumors: a pediatric brain tumor consortium report.
|
Clin Cancer Res
|
2007
|
1.34
|
|
27
|
Genomic analysis of diffuse pediatric low-grade gliomas identifies recurrent oncogenic truncating rearrangements in the transcription factor MYBL1.
|
Proc Natl Acad Sci U S A
|
2013
|
1.33
|
|
28
|
Visual outcomes in children with neurofibromatosis type 1-associated optic pathway glioma following chemotherapy: a multicenter retrospective analysis.
|
Neuro Oncol
|
2012
|
1.27
|
|
29
|
Region-specific radiotherapy and neuropsychological outcomes in adult survivors of childhood CNS malignancies.
|
Neuro Oncol
|
2010
|
1.27
|
|
30
|
Phase I trial of pirfenidone in children with neurofibromatosis 1 and plexiform neurofibromas.
|
Pediatr Neurol
|
2007
|
1.25
|
|
31
|
Advances in the diagnosis, molecular genetics, and treatment of pediatric embryonal CNS tumors.
|
Oncologist
|
2003
|
1.24
|
|
32
|
Symptomatology of autism spectrum disorder in a population with neurofibromatosis type 1.
|
Dev Med Child Neurol
|
2012
|
1.24
|
|
33
|
Late-occurring neurologic sequelae in adult survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study.
|
J Clin Oncol
|
2009
|
1.23
|
|
34
|
Phase I study of vismodegib in children with recurrent or refractory medulloblastoma: a pediatric brain tumor consortium study.
|
Clin Cancer Res
|
2013
|
1.20
|
|
35
|
Lovastatin as treatment for neurocognitive deficits in neurofibromatosis type 1: phase I study.
|
Pediatr Neurol
|
2011
|
1.18
|
|
36
|
Outcome of children with metastatic medulloblastoma treated with carboplatin during craniospinal radiotherapy: a Children's Oncology Group Phase I/II study.
|
J Clin Oncol
|
2012
|
1.17
|
|
37
|
Phase I and pharmacokinetic study of the oral farnesyltransferase inhibitor lonafarnib administered twice daily to pediatric patients with advanced central nervous system tumors using a modified continuous reassessment method: a Pediatric Brain Tumor Consortium Study.
|
J Clin Oncol
|
2007
|
1.17
|
|
38
|
Current treatment of medulloblastoma: recent advances and future challenges.
|
Semin Oncol
|
2004
|
1.16
|
|
39
|
Comparative multidimensional molecular analyses of pediatric diffuse intrinsic pontine glioma reveals distinct molecular subtypes.
|
Acta Neuropathol
|
2013
|
1.15
|
|
40
|
Children's Oncology Group's 2013 blueprint for research: central nervous system tumors.
|
Pediatr Blood Cancer
|
2012
|
1.14
|
|
41
|
The cerebellar mutism syndrome and its relation to cerebellar cognitive function and the cerebellar cognitive affective disorder.
|
Dev Disabil Res Rev
|
2008
|
1.13
|
|
42
|
Central nervous system meningiomas in the first two decades of life: a clinicopathological analysis of 87 patients.
|
J Neurosurg
|
2005
|
1.12
|
|
43
|
Medulloblastoma Down Under 2013: a report from the third annual meeting of the International Medulloblastoma Working Group.
|
Acta Neuropathol
|
2013
|
1.12
|
|
44
|
Biological background of pediatric medulloblastoma and ependymoma: a review from a translational research perspective.
|
Neuro Oncol
|
2008
|
1.12
|
|
45
|
Gender as a disease modifier in neurofibromatosis type 1 optic pathway glioma.
|
Ann Neurol
|
2014
|
1.12
|
|
46
|
Phase I trial of lapatinib in children with refractory CNS malignancies: a Pediatric Brain Tumor Consortium study.
|
J Clin Oncol
|
2010
|
1.10
|
|
47
|
Costello and cardio-facio-cutaneous syndromes: Moving toward clinical trials in RASopathies.
|
Am J Med Genet C Semin Med Genet
|
2011
|
1.10
|
|
48
|
A phase I and biology study of gefitinib and radiation in children with newly diagnosed brain stem gliomas or supratentorial malignant gliomas.
|
Eur J Cancer
|
2010
|
1.09
|
|
49
|
Ganglion cell layer-inner plexiform layer thickness and vision loss in young children with optic pathway gliomas.
|
Invest Ophthalmol Vis Sci
|
2014
|
1.07
|
|
50
|
Phase II trial of tipifarnib and radiation in children with newly diagnosed diffuse intrinsic pontine gliomas.
|
Neuro Oncol
|
2011
|
1.05
|
|
51
|
Long-term efficacy and toxicity of bevacizumab-based therapy in children with recurrent low-grade gliomas.
|
Pediatr Blood Cancer
|
2012
|
1.03
|
|
52
|
Phase I study of O6-benzylguanine and temozolomide administered daily for 5 days to pediatric patients with solid tumors.
|
J Clin Oncol
|
2005
|
1.03
|
|
53
|
Myeloablative chemotherapy with autologous bone marrow rescue in children and adolescents with recurrent malignant astrocytoma: outcome compared with conventional chemotherapy: a report from the Children's Oncology Group.
|
Pediatr Blood Cancer
|
2008
|
0.98
|
|
54
|
Ocular late effects in childhood and adolescent cancer survivors: a report from the childhood cancer survivor study.
|
Pediatr Blood Cancer
|
2010
|
0.98
|
|
55
|
Intracranial neoplasms in children with neurofibromatosis 1.
|
J Child Neurol
|
2002
|
0.98
|
|
56
|
Efficacy of bevacizumab plus irinotecan in children with recurrent low-grade gliomas--a Pediatric Brain Tumor Consortium study.
|
Neuro Oncol
|
2013
|
0.98
|
|
57
|
Phase II study of pre-irradiation chemotherapy for childhood intracranial ependymoma. Children's Cancer Group protocol 9942: a report from the Children's Oncology Group.
|
Pediatr Blood Cancer
|
2012
|
0.97
|
|
58
|
A phase II study of O6-benzylguanine and temozolomide in pediatric patients with recurrent or progressive high-grade gliomas and brainstem gliomas: a Pediatric Brain Tumor Consortium study.
|
J Neurooncol
|
2011
|
0.96
|
|
59
|
Radiation, atherosclerotic risk factors, and stroke risk in survivors of pediatric cancer: a report from the Childhood Cancer Survivor Study.
|
Int J Radiat Oncol Biol Phys
|
2013
|
0.95
|
|
60
|
Primary spinal cord tumors of childhood: effects of clinical presentation, radiographic features, and pathology on survival.
|
J Neurooncol
|
2009
|
0.95
|
|
61
|
Feasibility and comparison of visual acuity testing methods in children with neurofibromatosis type 1 and/or optic pathway gliomas.
|
Invest Ophthalmol Vis Sci
|
2013
|
0.95
|
|
62
|
Lovastatin regulates brain spontaneous low-frequency brain activity in neurofibromatosis type 1.
|
Neurosci Lett
|
2012
|
0.95
|
|
63
|
Challenges with defining response to antitumor agents in pediatric neuro-oncology: a report from the response assessment in pediatric neuro-oncology (RAPNO) working group.
|
Pediatr Blood Cancer
|
2013
|
0.93
|
|
64
|
Feasibility of metronomic maintenance chemotherapy following high-dose chemotherapy for malignant central nervous system tumors.
|
Pediatr Blood Cancer
|
2008
|
0.93
|
|
65
|
Neurocognitive dysfunction in children with neurofibromatosis type 1.
|
Curr Neurol Neurosci Rep
|
2003
|
0.92
|
|
66
|
Lack of efficacy of bevacizumab + irinotecan in cases of pediatric recurrent ependymoma--a Pediatric Brain Tumor Consortium study.
|
Neuro Oncol
|
2012
|
0.92
|
|
67
|
Insights into pediatric diffuse intrinsic pontine glioma through proteomic analysis of cerebrospinal fluid.
|
Neuro Oncol
|
2012
|
0.92
|
|
68
|
A feasibility and efficacy study of rapamycin and erlotinib for recurrent pediatric low-grade glioma (LGG).
|
Pediatr Blood Cancer
|
2012
|
0.92
|
|
69
|
Phase II study of thalidomide and radiation in children with newly diagnosed brain stem gliomas and glioblastoma multiforme.
|
J Neurooncol
|
2006
|
0.92
|
|
70
|
Endocrine outcome in children with medulloblastoma treated with 18 Gy of craniospinal radiation therapy.
|
Neuro Oncol
|
2004
|
0.91
|
|
71
|
Phase II trial of pirfenidone in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas.
|
Pediatr Blood Cancer
|
2014
|
0.90
|
|
72
|
Outcome for children <4 years of age with malignant central nervous system tumors treated with high-dose chemotherapy and autologous stem cell rescue.
|
Pediatr Blood Cancer
|
2007
|
0.88
|
|
73
|
Optimizing biologically targeted clinical trials for neurofibromatosis.
|
Expert Opin Investig Drugs
|
2013
|
0.88
|
|
74
|
The use of gene expression analysis to gain insights into signaling mechanisms of metastatic medulloblastoma.
|
Pediatr Neurosurg
|
2003
|
0.87
|
|
75
|
Advances in the management of low-grade gliomas.
|
Curr Oncol Rep
|
2014
|
0.86
|
|
76
|
Neurofibromas in children with neurofibromatosis 1.
|
J Child Neurol
|
2002
|
0.86
|
|
77
|
Modulation of the Wnt/beta-catenin pathway in human oligodendroglioma cells by Sox17 regulates proliferation and differentiation.
|
Cancer Lett
|
2013
|
0.85
|
|
78
|
Treatment developments and the unfolding of the quality of life discussion in childhood medulloblastoma: a review.
|
Childs Nerv Syst
|
2014
|
0.85
|
|
79
|
Back to the future: proceedings from the 2010 NF Conference.
|
Am J Med Genet A
|
2010
|
0.84
|
|
80
|
Current approaches to CNS tumors in infants and very young children.
|
Expert Rev Neurother
|
2004
|
0.84
|
|
81
|
Histological predictors of outcome in ependymoma are dependent on anatomic site within the central nervous system.
|
Brain Pathol
|
2013
|
0.84
|
|
82
|
Isolated extracranial recurrence of anaplastic ependymoma.
|
Pediatr Blood Cancer
|
2011
|
0.83
|
|
83
|
Progress in the treatment of childhood brain tumors: no room for complacency.
|
Pediatr Hematol Oncol
|
2006
|
0.83
|
|
84
|
Bevacizumab (BVZ)-associated toxicities in children with recurrent central nervous system tumors treated with BVZ and irinotecan (CPT-11): a Pediatric Brain Tumor Consortium Study (PBTC-022).
|
Cancer
|
2013
|
0.83
|
|
85
|
Germinoma: unusual imaging and pathological characteristics. Report of two cases.
|
J Neurosurg
|
2006
|
0.82
|
|
86
|
Aicardi syndrome: spectrum of disease and long-term prognosis in 77 females.
|
Pediatr Neurol
|
2002
|
0.82
|
|
87
|
Treatment Options for Medulloblastoma and CNS Primitive Neuroectodermal Tumor (PNET).
|
Curr Treat Options Neurol
|
2013
|
0.82
|
|
88
|
Tumors of the central nervous system: clinical aspects, molecular mechanisms, unanswered questions, and future research directions.
|
J Child Neurol
|
2008
|
0.81
|
|
89
|
Cognitive profiles of neurofibromatosis type 1 patients with minor brain malformations.
|
Pediatr Neurol
|
2012
|
0.81
|
|
90
|
Intellectual and academic outcome following two chemotherapy regimens and radiotherapy for average-risk medulloblastoma: COG A9961.
|
Pediatr Blood Cancer
|
2013
|
0.81
|
|
91
|
CTF meeting 2012: Translation of the basic understanding of the biology and genetics of NF1, NF2, and schwannomatosis toward the development of effective therapies.
|
Am J Med Genet A
|
2014
|
0.81
|
|
92
|
Outcome and prognostic factors for children with supratentorial primitive neuroectodermal tumors treated with carboplatin during radiotherapy: a report from the Children's Oncology Group.
|
Pediatr Blood Cancer
|
2015
|
0.80
|
|
93
|
Biologically targeted therapeutics in pediatric brain tumors.
|
Pediatr Neurol
|
2012
|
0.80
|
|
94
|
Pediatric brain tumors and epilepsy.
|
Semin Pediatr Neurol
|
2012
|
0.80
|
|
95
|
Neuro-oncology: understanding the molecular complexity of medulloblastoma.
|
Nat Rev Neurol
|
2012
|
0.77
|
|
96
|
Antioxidant enzyme polymorphisms and neuropsychological outcomes in medulloblastoma survivors: a report from the Childhood Cancer Survivor Study.
|
Neuro Oncol
|
2012
|
0.77
|
|
97
|
Radiation therapy quality in CCG/POG intergroup 9961: implications for craniospinal irradiation and the posterior fossa boost in future medulloblastoma trials.
|
Front Oncol
|
2012
|
0.77
|
|
98
|
Reduction of health status 7 years after addition of chemotherapy to cranio-spinal irradiation for medulloblastoma: a follow-up study on PNET-3 trial survivors.
|
Curr Neurol Neurosci Rep
|
2008
|
0.77
|
|
99
|
Radiation-induced neurocognitive decline: the risks and benefits of reducing the amount of whole-brain irradiation.
|
Curr Neurol Neurosci Rep
|
2002
|
0.77
|
|
100
|
Cumulative cisplatin dose is not associated with event-free or overall survival in children with newly diagnosed average-risk medulloblastoma treated with cisplatin based adjuvant chemotherapy: report from the Children's Oncology Group.
|
Pediatr Blood Cancer
|
2013
|
0.77
|
|
101
|
Medulloblastoma/Primitive neuroectodermal tumor and germ cell tumors: the uncommon but potentially curable primary brain tumors.
|
Hematol Oncol Clin North Am
|
2012
|
0.76
|
|
102
|
Impact of molecular biology studies on the understanding of brain tumors in childhood.
|
Curr Oncol Rep
|
2012
|
0.76
|
|
103
|
Visual outcomes in children with neurofibromatosis type 1 and orbitotemporal plexiform neurofibromas.
|
Am J Ophthalmol
|
2013
|
0.76
|
|
104
|
Medulloblastoma.
|
J Neurosurg
|
2005
|
0.76
|
|
105
|
Neurotoxicity of biologically targeted agents in pediatric cancer trials.
|
Pediatr Neurol
|
2012
|
0.75
|
|
106
|
A phase I trial and PK study of cediranib (AZD2171), an orally bioavailable pan-VEGFR inhibitor, in children with recurrent or refractory primary CNS tumors.
|
Childs Nerv Syst
|
2015
|
0.75
|
|
107
|
Neurocognitive sequelae of cancer treatment.
|
Neurology
|
2002
|
0.75
|
|
108
|
Phase I trial of weekly MK-0752 in children with refractory central nervous system malignancies: a pediatric brain tumor consortium study.
|
Childs Nerv Syst
|
2015
|
0.75
|
|
109
|
A review of secondary central nervous system tumors after treatment of a primary pediatric malignancy.
|
Semin Pediatr Neurol
|
2012
|
0.75
|
|
110
|
Neurotoxicity of chemotherapeutic and biologic agents in children with cancer.
|
Curr Neurol Neurosci Rep
|
2008
|
0.75
|
|
111
|
Child neurology: the role of the pediatric neurologist both within and outside the academic setting.
|
Pediatr Neurol
|
2011
|
0.75
|
|
112
|
International telemedicine consultations for neurodevelopmental disabilities.
|
Telemed J E Health
|
2014
|
0.75
|
|
113
|
Neurocognitive deficits in children with neurofibromatosis type 1.
|
Curr Neurol Neurosci Rep
|
2006
|
0.75
|
|
114
|
Preradiation chemotherapy versus radiotherapy alone for nonmetastatic medulloblastoma.
|
Curr Neurol Neurosci Rep
|
2004
|
0.75
|
|
115
|
Pediatric brain tumors.
|
Continuum (Minneap Minn)
|
2015
|
0.75
|